THROMBOSIS RESEARCH is a leading peer-reviewed journal in the field of hematology, published by PERGAMON-ELSEVIER SCIENCE LTD. With an impressive impact factor and ranked within the top 10 of 137 in its category according to Scopus, this journal provides a critical platform for the dissemination of innovative research related to thrombosis and hemostasis. Established in 1972, THROMBOSIS RESEARCH has been at the forefront of scholarly communication, addressing key issues, findings, and advancements over more than five decades. Recognized for its high-quality content, the journal is categorized in the Q1 quartile for 2023, reflecting its influence and relevance within the scientific community. Researchers, medical professionals, and students engaged in the study of blood disorders will find valuable insights and the latest discoveries within its pages. Although currently not an open-access publication, THROMBOSIS RESEARCH remains accessible to a wide audience through institutional subscriptions, ensuring that vital research continues to inform and enhance clinical practices around the globe.

HYPERTENSION, published by Lippincott Williams & Wilkins, is a preeminent journal in the field of cardiovascular medicine, focusing on the latest research, therapies, and clinical practices related to hypertension and its associated disorders. With a distinguished Q1 ranking in Internal Medicine and a commendable Scopus rank of #12 out of 167 in its category, it occupies a vital position within the academic community, appealing to researchers, clinicians, and educators alike. The journal has been disseminating impactful findings since 1979 and continues to influence the discourse on hypertension through rigorous peer-reviewed articles, reviews, and studies designed to elevate understanding and treatment of this prevalent condition. HYPERTENSION remains an essential resource for professionals keen on advancing their knowledge in this critical area of medicine, fostering innovations that ultimately improve patient care.

American Journal of Hypertension, published by Oxford University Press, is a leading peer-reviewed journal dedicated to the field of hypertension and cardiovascular health. With an ISSN of 0895-7061 and an E-ISSN of 1941-7225, this prestigious journal has been providing researchers and clinicians with significant advancements in hypertension research since its inception in 1954, with a continued focus on innovative studies through 2024. Ranked Q2 in Internal Medicine and positioned within the top 22% of its category according to Scopus, it is a vital resource for those involved in clinical practice and research aimed at understanding and managing hypertension. The journal disseminates pivotal findings, treatment updates, and guideline recommendations that contribute to improved patient care globally. Accessible solely through subscription, the American Journal of Hypertension is essential reading for professionals committed to enhancing cardiovascular health outcomes.

Clinica e Investigacion en Arteriosclerosis is a premier academic journal dedicated to the field of cardiology and cardiovascular medicine, published by ELSEVIER. With its ISSN 0214-9168 and E-ISSN 1578-1879, the journal aims to disseminate high-quality research and innovations in the understanding and treatment of arterial diseases, contributing significantly to both clinical practices and pharmacological advancements. Established in 2007 and continuing into 2024, the journal has garnered recognition with a notable Q3 categorization in both Cardiology and Cardiovascular Medicine and Pharmacology (medical) for 2023, reflecting its impact in the academic community. Researchers and healthcare professionals utilizing this journal will find a diverse range of articles exploring novel therapeutic strategies and epidemiological data, making it an essential resource for advancing knowledge and practice in cardiovascular health. While it does not operate as an open-access journal, the findings published in Clinica e Investigacion en Arteriosclerosis are pivotal for understanding current trends and future directions in cardiovascular research.

Kidney & Blood Pressure Research, published by KARGER, is a premier open-access journal dedicated to the evolving fields of nephrology and cardiovascular medicine. Since its inception in 1978 and with a forward-looking scope extending to 2024, this journal plays a vital role in disseminating innovative research and clinical findings related to kidney health and blood pressure regulation. With an impressive 2023 Impact Factor and ranked in the second quartile (Q2) in both cardiology and nephrology categories, it is recognized as a significant resource among its peers, including a Scopus rank of #23 in Nephrology and #128 in Cardiology. The journal's commitment to open access since 2013 further ensures that cutting-edge research is readily available to the global scientific community. Based in Switzerland, the journal not only fosters academic collaboration but also addresses critical health challenges related to kidney function and hypertension. It is a crucial platform for researchers, healthcare professionals, and students alike, encouraging the ongoing dialogue and advancement of knowledge in these critical areas of health.

The European Journal of Heart Failure, published by Wiley, is a premier international journal dedicated to advancing the field of cardiology, specifically focusing on heart failure research and clinical practices. With an impressive impact factor and ranked in the top 1% of journals in Cardiology and Cardiovascular Medicine according to Scopus rankings (Rank #7/387, Percentile 98th), this journal serves as a vital resource for researchers, clinicians, and students alike. Spanning from 1999 to 2024, the journal has established itself as a cornerstone for innovative research, comprehensive reviews, and clinical insights, fostering a deeper understanding of heart failure mechanisms, management, and treatment strategies. Although not an open-access journal, the European Journal of Heart Failure remains committed to disseminating high-quality, peer-reviewed content that contributes significantly to the global cardiovascular community. Located in the United States at 111 River St, Hoboken, NJ 07030-5774, it continues to play an essential role in shaping the future of heart failure management.

The Canadian Respiratory Journal is a prominent peer-reviewed publication dedicated to advancing knowledge in the field of pulmonary and respiratory medicine. Published by HINDAWI LTD and based in Egypt, this journal has been an Open Access platform since 1994, ensuring broad dissemination of vital research findings to a global audience. With an ISSN of 1198-2241 and an E-ISSN of 1916-7245, the journal plays a significant role in shaping respiratory health discussions, evidenced by its 2023 category rankings of Q2 in Medicine (miscellaneous) and Q3 in Pulmonary and Respiratory Medicine. The journal consistently publishes high-quality research, reviews, and clinical guidelines that resonate with practitioners, researchers, and students alike. It serves as an essential resource for those seeking to stay at the forefront of developments in respiratory health, reflecting its commitment to enhancing practice and informing policy while recognizing its place in this vital medical field.

INTERNATIONAL JOURNAL OF OBESITY, published by SpringerNature, stands as a premier multidisciplinary platform for research in the fields of Endocrinology, Diabetes and Metabolism, Nutrition and Dietetics, as well as Miscellaneous Medicine. With a remarkable impact, the journal is consistently positioned in the Q1 category across these critical areas, underscoring its significance in advancing the understanding of obesity and its related health outcomes. Established in 1977 and covering a broad spectrum of studies until 2024, it boasts a notable Scopus Rank reflecting its influential contributions to the scientific community, including a rank of 14 out of 140 in Nutrition and Dietetics. The INTERNATIONAL JOURNAL OF OBESITY is not just a repository of knowledge but a vital resource for researchers, clinicians, and students aiming to explore the complexities of obesity and develop evidence-based interventions. Despite not being an open-access journal, its rigorous peer-reviewed articles remain accessible to those within academic institutions, facilitating an essential dialogue among professionals dedicated to this critical global health issue.

Rheumatology & Autoimmunity, published by WILEY, is an emerging academic journal that delves into the intricacies of rheumatological diseases and autoimmune disorders, providing a critical platform for researchers and practitioners within the field. With an ISSN of 2767-1410 and E-ISSN 2767-1429, the journal aims to disseminate cutting-edge research in both clinical and laboratory settings, enhancing knowledge and understanding among professionals and scholars. Although currently classified in Q4 for Immunology and Allergy, and Q3 for Internal Medicine and Rheumatology as of 2023, the journal is positioned for growth and greater visibility in the scientific community. The three-year publishing span from 2021 to 2024 signifies a commitment to addressing contemporary issues and fostering collaboration among various disciplines related to immunology. As an open access journal, it provides wide accessibility, ensuring that groundbreaking research is available to a broad audience. This journal is poised to become a vital resource for those dedicated to advancing the understanding and treatment of autoimmune conditions.

The International Journal of Hypertension, published by HINDAWI LTD, is a pivotal open-access journal dedicated to advancing knowledge in the field of hypertension and cardiovascular health. Since its inception in 2010, the journal has provided a vital platform for researchers, clinicians, and students to disseminate innovative findings and comprehensive reviews spanning various aspects of hypertension management, pathophysiology, and epidemiology. Residing in Q3 of the Internal Medicine category and ranked 75 out of 167 in the Scopus rankings, it reflects a commitment to quality and relevance in medical research. With a global reach, the journal aims to foster collaboration and knowledge exchange, contributing significantly to the scientific community's efforts to combat hypertension-related health issues. Accessible since 2010, this journal exemplifies the principles of open science, ensuring that critical research is available to all stakeholders in the field.